Tarsus Pharmaceuticals, Inc. TARS Total costs & expenses
Total costs & expenses at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostsAndExpenses.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s total costs & expenses?
- Tarsus Pharmaceuticals, Inc. (TARS) reported total costs & expenses of $168.18M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s total costs & expenses changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s total costs & expenses increased by 60.8% year-over-year, from $104.62M to $168.18M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s total costs & expenses?
- Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s total costs & expenses has grown at a 80.7% compound annual growth rate (CAGR), from $88.53M to $522.33M.
- What does total costs & expenses mean?
- This metric represents the aggregate sum of all operating and non-operating costs incurred by the company to support its business activities during a specific period. It encompasses research and development investments, selling, general, and administrative expenses, and other operational outlays required to sustain commercial operations. Monitoring this figure helps investors assess the company's overall cost structure and operational efficiency relative to its revenue generation.